| Nov 4 |
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
|
| Oct 18 |
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
|
| Sep 23 |
Actinium Pharmaceuticals reports data from Phase III trial of AML treatment
|
| Sep 20 |
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
|
| Aug 5 |
Actinium: Q2 Earnings Snapshot
|
| Aug 5 |
Sector Update: Health Care Stocks Fall in Afternoon Trading
|
| Aug 5 |
Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment
|
| Aug 5 |
Actinium stock tumbles 75% on FDA update for lomab-B
|
| Aug 5 |
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
|
| Aug 1 |
Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
|
